Prosecution Insights
Last updated: April 19, 2026
Application No. 18/253,308

DETECTION METHOD

Non-Final OA §102§103§112
Filed
May 17, 2023
Examiner
XU, XIAOYUN
Art Unit
1797
Tech Center
1700 — Chemical & Materials Engineering
Assignee
The University of Queensland
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
3y 2m
To Grant
92%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allow Rate
687 granted / 1154 resolved
-5.5% vs TC avg
Strong +32% interview lift
Without
With
+32.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
55 currently pending
Career history
1209
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
61.1%
+21.1% vs TC avg
§102
17.8%
-22.2% vs TC avg
§112
13.3%
-26.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1154 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Preliminary Amendment filed on 05/17/2023 is acknowledged. Claims 1-12 are pending in the application and are considered on merits. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 1-9 and 11-12 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites “silyl protecting group” without specifically defining the structure which renders the claim unclear and indefinite, sine it is not apparent as to what silyl protecting group is recited in the claim. Claim 2 and 9 recite “R8aR8bR8c” without specifically defining the structure which renders the claim unclear and indefinite, sine it is not apparent as to what R8aR8bR8c is recited in the claim. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 1-6 is/are rejected under 35 U.S.C. 103 as being unpatentable over Wu et al. (CN 111410664, IDS) (Wu) in view of Xiong et al. (Analytical Chemistry, 2013, IDS) (Xiong). Regarding claim 1, Wu teaches a method for detecting a nerve agent in an analyte, said nerve agent having a phosphorus-fluorine bond (par [0002]), which method comprises: (a) contacting the analyte with a composition comprising a sensor compound; wherein the sensor compound comprises a basic nitrogen atom and a hydroxyaryl moiety protected by a silyl protecting group (par [0008]); and wherein, in the presence of hydrogen fluoride, said silyl group is cleaved to effect deprotection of the hydroxyl group thus forming a luminescent reporter compound (par [0023]); (b) irradiating the composition at a predetermined wavelength (par [0023]); ( c) measuring the luminescence to determine if the reporter compound is present (par [0023]); and ( d) determining whether the nerve agent is present in the analyte based on the measurement obtained in step ( c ) (par [0023]). Wu does not specifically teach that the sensor composition is in solid state. However, in the analogous art of fluoride anion sensor, Xiong teaches that the sensor composition is in solid state (page 4115, par 1). Xiong teaches that “Herein, we invented a new method for detection by adopting the hydrogel as the supporter of reaction between a water insoluble fluorescent probe and in the water environment. This method is highly rapid, selective, and sensitive, which can determine levels in 15 s at the drinking water standard…. just a few microliter samples were required in the analysis procedures with this method” (abstract). It would have been obvious to one of ordinary skill in the art to use the solid state composition sensor, in order to obtain the benefit of “highly rapid, selective, and sensitive” detection. Regarding claim 2, Wu teaches that wherein the sensor compound has the Formula (IA) (par [0008]): wherein: A is an optionally substituted aryl group (par [0008]); X is S, Y is CR3, and Z is CR4 (par [0008]); R3 is H (par [0008]), R4 is H (par [0008]). Regarding claim 3, the phrase “the method is for vapour phase detection” merely describes an intended use of the method, and does not further limit the step of the method. Therefore, caries no weight in patentability determination. Regarding claim 4, the phrase “the method is for detection of contamination on a surface” merely describes an intended use of the method, and does not further limit the step of the method. Therefore, caries no weight in patentability determination. Regarding claim 5, Wu discloses a sensing device for detection of a nerve agent in an analyte (par [0002]), said nerve agent having a P-F bond (par [0002]), the sensing device comprising: A composition comprising a sensor compound wherein the sensor compound comprises a basic nitrogen atom and a hydroxyaryl moiety protected by a silyl protecting group (par [0008]); and wherein, in the presence of hydrogen fluoride, said silyl group is cleaved to de-protect the hydroxyl group thus forming a luminescent reporter compound (par [0023]); an irradiation source for irradiating the reporter compound with stimulating radiation at a predetermined wavelength (par [0023]); a detector for measuring luminescence of the optical sensing element (par [0023]); means for relating to an operator the luminescence measured by the detector (par [0023]); and means for delivering the analyte for contacting with the sensor compound (par [0023]). Wu does not specifically disclose that the sensor composition is in solid state. However, in the analogous art of fluoride anion sensor, Xiong teaches that the sensor composition is in solid state (page 4115, par 1). Xiong teaches that “Herein, we invented a new method for detection by adopting the hydrogel as the supporter of reaction between a water insoluble fluorescent probe and in the water environment. This method is highly rapid, selective, and sensitive, which can determine levels in 15 s at the drinking water standard…. just a few microliter samples were required in the analysis procedures with this method” (abstract). It would have been obvious to one of ordinary skill in the art to use the solid state composition sensor, in order to obtain the benefit of “highly rapid, selective, and sensitive” detection. Regarding claim 6, Xiong discloses wherein the solid state sensor compound is comprised in a film, a coating on a substrate, a swab or an optical sensing element (page 4115, par 1). Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 7-12 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Wu et al. (CN 111410664, IDS) (Wu). Regarding claim 7, Wu discloses an optical sensing element for detection of a nerve agent having a phosphorus-fluorine bond (par [0002]), wherein said sensing element comprises a compound comprising a basic nitrogen atom and a hydroxyaryl moiety protected by a silyl protecting group (par [0008]); and wherein, in the presence of hydrogen fluoride, said silyl group is cleaved to de-protect the hydroxyl group thus forming a luminescent reporter compound (par [0023]). Regarding claim 8, Wu discloses a sensor compound of Formula (IA), (IB), (IC), (ID), (IE) or (IF) (par [0008]). Regarding claim 9, Wu discloses a sensor compound of Formula (IA) (par [0008]): wherein: A is an optionally substituted aryl group (par [0008]); X is S, Y is CR3, and Z is CR4 (par [0008]); R3 is H (par [0008]), R4 is H (par [0008]). Regarding claim 10, Wu discloses a sensor compound according to claim 9 selected from SQF1148, SQF1323, SQF1360, SQF1370, SQF1382, SQF1388, SQF1389, SQF1399, SQF13100, SQF13111, SQF1344, SQF1352, SQF1140, SQF1393, SQF1394, SQF1395, and SQF1396 (par [0008]). Regarding claim 11, Wu discloses use of a compound according to claim 8 for detecting a nerve agent, wherein said nerve agent has a phosphorus-fluorine bond (par [0002][0008]). Regarding claim 12, Wu discloses that wherein the nerve agent is a G-series nerve agent, preferably Sarin, Cyclosarin or Soman (par [0002]). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to XIAOYUN R XU, Ph. D. whose telephone number is (571)270-5560. The examiner can normally be reached M-F 8am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lyle Alexander can be reached at 571-272-1254. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /XIAOYUN R XU, Ph.D./ Primary Examiner, Art Unit 1797
Read full office action

Prosecution Timeline

May 17, 2023
Application Filed
Nov 14, 2025
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12602776
METHOD AND APPARATUS FOR ANALYZING BIOCHIP IMAGE, COMPUTER DEVICE, AND STORAGE MEDIUM
2y 5m to grant Granted Apr 14, 2026
Patent 12578346
SYSTEMS AND METHODS FOR GLYCOPEPTIDE CONCENTRATION DETERMINATION, NORMALIZED ABUNDANCE DETERMINATION, AND LC/MS RUN SAMPLE PREPARATION
2y 5m to grant Granted Mar 17, 2026
Patent 12571806
METHOD FOR ASSISTING DETECTION OF NON-ALCOHOLIC STEATOHEPATITIS
2y 5m to grant Granted Mar 10, 2026
Patent 12560617
Method of Diagnosing and Treatment Monitoring of Crohn's Disease and Ulcerative Colitis
2y 5m to grant Granted Feb 24, 2026
Patent 12553868
KIND OF METHOD FOR DETECTING SIALOGLYCOSYL CASEIN GLYCOMACROPEPTIDE
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
92%
With Interview (+32.5%)
3y 2m
Median Time to Grant
Low
PTA Risk
Based on 1154 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month